The Company SpaceX Made Relevant Again: Rocket Lab's Defense Pivot Changes Everything

Hawkmont Research | Equity Research | Space Economy & Defense June 18, 2026 | INITIATING COVERAGE

This report is produced independently by Hawkmont Research. No compensation was received from any company mentioned herein. All prices and market data as of June 18, 2026 unless otherwise noted. This is not investment advice. Please read full disclosures at the end of this report.

Rocket Lab Corporation (Nasdaq: RKLB) | No Rating | Current Price: ~$104.53 | Market Cap: ~$60.6 billion

Metric	Value
Market Cap	~$60.6 billion
52-Week Range	$25.71 / $151.00
Q1 2026 Revenue	$200.3 million (+63.5% YoY)
Q2 2026 Revenue Guidance	$225M to $240M
FY2025 Revenue	$602 million (+38% YoY)
Backlog	$2.2 billion (+108% YoY)
Cash / Liquidity	$1.48B cash; $2.0B+ total liquidity
Adjusted EBITDA (Q1 2026)	($11.8M) -- better than guided
Trailing P/E	Negative (not yet profitable)
Next Earnings	August 6, 2026

THESIS: Rocket Lab is no longer a small-satellite launch company. The market knew it first -- RKLB has quadrupled over the past year. The question now is whether the underlying business justifies a $60 billion valuation for a company still burning cash. Hawkmont Research initiates coverage on RKLB with no rating. The growth story is real. The defense contract portfolio is transformational. Neutron is the defining risk. The valuation embeds assumptions that leave no room for error. This is not a report recommending a position. It is a report explaining what Rocket Lab actually is, what it is becoming, and what you need to believe to own it at these prices.

Table of Contents

1. Executive Summary

2. From Launch Company to Space Prime: The Strategic Transformation

3. Electron: The Revenue Engine That Built the Platform

4. HASTE and the Defense Pivot: Why the Pentagon Matters More Than Commercial

5. Space Systems: The Margin Expansion Engine

6. Neutron: The Binary Bet That Defines the Next Chapter

7. The SpaceX IPO Effect: Tailwind, Headwind, or Both?

8. Financial Analysis and Valuation

9. Scenario Analysis

10. Risks to the Thesis

11. Disclosures

Section 1: Executive Summary

Rocket Lab was founded in 2006 by Peter Beck in a garage in New Zealand. The pitch was simple: small satellites need a dedicated ride to orbit, not a shared bus with ten other payloads on a SpaceX manifest. Electron was built to solve that problem. It has now flown nearly 90 times, and Rocket Lab has signed more launch contracts in Q1 2026 alone than it flew missions in all of 2025.

That sentence is worth stopping on. It describes a company that has broken out of its launch cadence constraints and into something structurally different: a defense prime contractor with a space systems integration business, a hypersonic test vehicle franchise, a $2.2 billion contracted backlog, and a medium-lift rocket targeting its first flight before year-end.

Q1 2026 revenue was $200.3 million, up 63.5% year-over-year. The company guided Q2 at $225 million to $240 million. It ended Q1 with over $2 billion in total liquidity. The backlog doubled from a year ago.

The bad news is that none of this is cheap. At roughly $60 billion in market cap on annualized revenue of approximately $900 million, RKLB trades at over 60 times trailing revenue. Morningstar has flagged the stock as trading at an 857% premium to its intrinsic value estimate. The market is pricing a future version of Rocket Lab that has successfully launched Neutron, captured meaningful medium-lift market share, and compounded its defense contract wins into recurring multi-year revenue at scale.

That version of Rocket Lab may well exist. The path from here to there is not without risk.

Hawkmont Research initiates coverage with no rating. The growth story is legitimate. The valuation is a leap of faith. Our objective is to give investors the tools to make that call for themselves.

Section 2: From Launch Company to Space Prime: The Strategic Transformation

Rocket Lab's investor pitch has changed substantially over the past 18 months. In 2024, the story was: Electron is the most reliable small-launch vehicle in the world, and the commercial small-satellite market is large and growing. That was true. It was also a capped narrative. Electron's payload capacity is approximately 300 kg to low Earth orbit. Its average selling price is around $8 million per mission. There is a ceiling on how large that business can get.

The transformation that makes RKLB interesting at a different scale has three components.

Defense prime contractor status. 

Rocket Lab is no longer a vendor to the Department of Defense. It is a prime. The Space Development Agency awarded Rocket Lab an $816 million contract to design and manufacture 18 satellites for the Tranche 3 Tracking Layer of the Proliferated Warfighter Space Architecture. This is the missile warning and tracking constellation at the center of U.S. space-based defense infrastructure. This contract came on top of an existing $515 million Transport Layer Tranche 2 program. The combined SDA exposure alone exceeds $1.3 billion. The company subsequently disclosed its largest-ever single order: a $190 million, 20-launch HASTE contract under the MACH-TB 2.0 program. Rocket Lab then earned a spot alongside Raytheon on the Golden Dome Space Based Interceptor program, the orbital interceptor layer of the administration's missile defense architecture.

Vertical integration. 

Rocket Lab builds most of what goes into its spacecraft in-house: solar arrays, reaction wheels, avionics, propulsion, payloads, and now laser communications following the acquisition of Mynaric AG. This is not standard practice in the space industry, where most companies buy components from suppliers. Rocket Lab's vertical integration model reduces lead times, improves margins over time, and creates a competitive moat that commodity launch providers cannot replicate. It also allows the company to bid on prime defense contracts credibly, because it can demonstrate end-to-end manufacturing capability.

Neutron. 

The medium-lift reusable rocket targeting its first flight in Q4 2026 is the option value embedded in the stock. Neutron can carry 13,000 kg to LEO -- an order of magnitude more payload than Electron. It targets the same class of missions as Falcon 9. If it works, Rocket Lab's total addressable market expands dramatically. Five commercial contracts are already signed. The national security case for a Falcon 9 alternative from a non-SpaceX provider is significant.

These three elements, taken together, describe a company that has outgrown its original business model and is building a new one in real time.

Section 3: Electron: The Revenue Engine That Built the Platform

Electron is approaching its 90th launch. In the commercial launch industry, launch vehicles that have flown 90 times are rare. Atlas V flew 86 times over 20 years. Electron has done it in less than a decade.

That operational cadence matters for two reasons. First, it generates the cash flow that funds everything else. Second, it generates the credibility that wins government contracts. When the Space Force selects a company to build 18 missile-tracking satellites, one of the key questions is: can this company execute? Rocket Lab has 90 missions worth of evidence.

Q1 2026 launch results: eight successful launches year-to-date. 31 new Electron and HASTE contracts signed in the quarter, the highest quarterly total in company history. The total launch manifest now exceeds 70 missions, the highest in company history.

Electron's average selling price is not going up dramatically. It is a mature vehicle on a known price curve. The launch business contributes approximately 32% of quarterly revenue ($63.7 million of Q1's $200.3 million). The growth is real but bounded. Electron is the platform, not the growth engine.

The growth engine is Space Systems.

Section 4: HASTE and the Defense Pivot: Why the Pentagon Matters More Than Commercial

HASTE -- the Hypersonic Accelerator Suborbital Test Environment -- is Electron configured for hypersonic test missions. It carries hypersonic payloads to near-space altitudes on suborbital trajectories, providing the DoD with a repeatable, affordable platform for testing next-generation weapons and sensors.

This is a franchise. The Pentagon is spending heavily on hypersonic capability. The threat environment from China and Russia has created an institutional urgency to test, iterate, and field hypersonic technology faster than the current acquisition system allows. HASTE provides a rapid test cadence that cannot be replicated on traditional ballistic ranges.

Q1 2026 HASTE highlights: a $190 million, 20-launch MACH-TB 2.0 contract with the Department of War. A three-launch contract with Anduril Industries for hypersonic capability delivery. The Golden Dome SBI selection alongside Raytheon.

To be precise on the Golden Dome positioning: Rocket Lab is not a prime contractor on the SBI program. Raytheon holds the prime slot. Rocket Lab is a subcontractor partner. The combined SBI contracts across all 12 selected teams represent up to $3.2 billion in combined OTA agreements. Rocket Lab's share of that figure has not been publicly quantified. The significance of the selection is not current revenue -- it is positioning. If the SBI program progresses from demonstration to development, Rocket Lab's role has potential to expand substantially.

The HASTE manifest now runs past 70 missions. That is a multi-year revenue backlog for a product line that did not exist three years ago.

Section 5: Space Systems: The Margin Expansion Engine

Space Systems is now the majority of Rocket Lab's revenue. Q1 2026: $136.7 million out of $200.3 million total. That is 68% of revenue from spacecraft engineering, components, satellite manufacturing, and on-orbit services.

This is the business that scales. Launch is operationally intensive -- every mission requires a rocket, a launch team, a pad, and a customer payload. Space Systems revenue comes from design contracts, component sales, and long-duration manufacturing programs. The $816 million SDA Tranche 3 contract alone spans multiple years. It does not require a rocket launch to generate revenue.

Gross margins tell the story. Q1 2026 GAAP gross margin was 38.2%. Non-GAAP was 43%. These are not the margins of a launch company. They are the margins of a high-value systems integrator.

The mix shift matters. As Space Systems grows as a proportion of total revenue, the blended margin profile improves. Q2 2026 guidance projects GAAP gross margin of 33% to 35% and non-GAAP of 38% to 40%, slightly below Q1 due to product mix within Space Systems. This is not a trend reversal -- it is quarterly lumpiness in contract delivery timing.

Recent acquisitions reinforce the integration strategy. Mynaric AG brings laser communications capability. Motiv Space Systems, announced in Q1, adds space robotics. Each acquisition adds a component that Rocket Lab can incorporate into its spacecraft designs, reducing external procurement and improving control over the supply chain.

The SDA contracts validate this model at scale. Rocket Lab competed against established defense primes for the Tranche 3 award and won. The vertical integration capability was the differentiator. That same capability is the moat.

Section 6: Neutron: The Binary Bet That Defines the Next Chapter

Everything in sections 2 through 5 is real. It is delivering revenue today. It underpins the backlog. It explains the stock's 750% increase over the past year.

Neutron is different. Neutron is a bet.

The vehicle targets 13,000 kg to LEO, making it a direct competitor to Falcon 9 in the medium-lift class. It is designed to be reusable -- the first stage returns to the pad, reducing per-launch cost on a recurring basis. First flight is targeted for Q4 2026. FAA launch permits have been filed. Hardware is coming together, per Q1 management commentary.

Five commercial contracts are already booked. The national security case is straightforward: the U.S. cannot rely indefinitely on a single commercial provider for medium-lift launch. SpaceX's Falcon 9 is the only credible Western vehicle in that class today. Neutron, if it works, changes that. Government customers will pay a premium for supply chain diversity.

The "if it works" part is not dismissible. Developing a new rocket is hard. The failure rate on first launches of new vehicles is not zero. Rocket Lab has built and flown Electron 89-plus times, which provides real engineering competence that reduces but does not eliminate execution risk. The development costs are ongoing -- Q2 2026 operating expense guidance of $138 million to $144 million GAAP reflects continued Neutron investment.

If Neutron achieves a successful first flight in Q4 2026, the re-rating of RKLB upward could be dramatic. Consensus analyst targets range from $97 to $150. KeyBanc's June 2026 upgrade to Overweight set a $135 target specifically citing Neutron's development timeline.

If Neutron is delayed into 2027, or if the first flight fails, the stock reprices downward. The current valuation embeds substantial Neutron optionality.

Neutron Outcome	Probability (HMR)	Stock Direction
Successful Q4 2026 first flight	35%	Significant upside; re-rates toward $135+
Delayed to H1 2027, eventually successful	40%	Modest near-term pressure; thesis intact
First flight failure, recovery uncertain	25%	Material downside; forces valuation reset

These probabilities are Hawkmont Research estimates. They are not company guidance.

Section 7: The SpaceX IPO Effect: Tailwind, Headwind, or Both?

SpaceX listed on Nasdaq on June 12, 2026, under the ticker SPCX. The IPO was the largest in market history, raising $75 billion at a valuation exceeding $1.75 trillion. The week of the listing was volatile for RKLB.

The initial reaction: RKLB sold off on the day of SpaceX's debut. The interpretation was capital siphon -- investors who owned RKLB as a SpaceX proxy rotated into the real thing.

The subsequent reaction: RKLB recovered. KeyBanc upgraded RKLB to Overweight on June 14, citing the selloff as an opportunity. Cantor Fitzgerald reiterated Buy on June 15.

The more durable question is what SpaceX's public market presence means for Rocket Lab over the next two to three years.

The tailwind case: 

SpaceX's IPO forces institutional analysts to model the space economy in detail for the first time. Supply-chain flows, competitive dynamics, government contract sizes, and launch economics become visible in audited financials. That analysis inevitably raises attention on Rocket Lab as the primary public-market alternative to SpaceX for medium-lift launch and defense satellite manufacturing. Rocket Lab's Nasdaq-100 inclusion, announced June 12 and effective June 22, adds index-tracking capital flows as a structural support.

The headwind case: 

SpaceX's post-IPO capital deployment will accelerate Starlink build-out and Starship development. Starship targeting the same heavy-lift class as Neutron is not a direct competitor -- Starship carries far more payload than Neutron's 13,000 kg target. But SpaceX's overall competitive position strengthens with more capital, and that compresses Rocket Lab's margin of safety on any assumption of medium-lift market share capture.

The Hawkmont view: 

The SpaceX IPO is a net tailwind for Rocket Lab's awareness and institutional credibility. The specific impact on the Neutron competitive thesis depends entirely on whether Rocket Lab delivers a successful first flight before SpaceX makes Falcon 9 replacement economics even more attractive. The race is on.

Section 8: Financial Analysis and Valuation

8.1 Income Statement Summary

Metric	FY2024	FY2025	Q1 2026	Q2 2026 Guidance
Revenue	$436M	$602M	$200.3M	$225M to $240M
Revenue Growth	--	+38%	+63.5% YoY	~57% YoY (midpoint)
GAAP Gross Margin	~21%	~33%	38.2%	33% to 35%
Non-GAAP Gross Margin	--	--	43%	38% to 40%
Adjusted EBITDA	(approx. $150M)	(approx. $120M)	($11.8M)	Not guided
Backlog	$1.07B	$1.85B	$2.2B	--

FY2025 annual revenue of $602 million represented 38% growth. Q1 2026 continued the acceleration. At the midpoint of Q2 guidance ($232.5 million), H1 2026 revenue would be $432.8 million -- essentially equal to all of FY2024. The trajectory is clear.

The profitability picture is more complicated. Rocket Lab is not profitable on a GAAP basis. Adjusted EBITDA is negative but narrowing. The Q1 2026 adjusted EBITDA loss of $11.8 million was better than guidance. The path to positive EBITDA runs through two mechanisms: revenue scale diluting fixed operating costs, and the Neutron program transitioning from development expense to revenue-generating asset.

The company is well-capitalized for the journey. Cash of $1.48 billion and total liquidity exceeding $2 billion provides a meaningful runway. Cash burn is manageable at current revenue scale; it becomes a non-issue if Neutron progresses on schedule.

8.2 Valuation

Metric	RKLB	Comparable Universe
Market Cap	~$60.6B	--
EV/Revenue (Trailing)	~65x	Mature defense primes: 2 to 3x
EV/Revenue (FY2026 est.)	~16 to 18x	High-growth defense tech: 8 to 15x
GAAP P/E	Negative	--
Revenue Growth (Q1 2026)	+63.5% YoY	--
Backlog/Revenue ratio	~2.4x	Above average for defense prime

There is no clean comparable for Rocket Lab at this stage. Traditional defense primes (Lockheed, Northrop, Raytheon) trade at 2 to 3 times revenue because they are mature, low-growth businesses. RKLB does not belong in that peer group. High-growth defense technology companies (Palantir, AXON, KTOS) trade at 8 to 15 times revenue. RKLB on a forward basis falls in this range as it approaches $900 million to $1 billion in annual revenue.

Morningstar's 857% premium flag is technically accurate in the context of a discounted cash flow model that does not assign credit for Neutron. If you strip out Neutron and model only Electron, HASTE, and Space Systems, the current stock price is expensive. If you assign probability-weighted value to a Neutron that captures even 10% of the medium-lift market, the math becomes defensible.

This is the core investor decision. Rocket Lab at $60 billion is a bet on Neutron. The existing business is growing fast and is real, but it does not intrinsically justify the current market cap without Neutron.

8.3 The Nasdaq-100 Inclusion

RKLB joins the Nasdaq-100 effective June 22, 2026. This is mechanically bullish near-term. Index funds and ETFs tracking the NDX must purchase shares. That is a known, time-limited demand driver. It does not change the fundamental thesis but provides a floor for the immediate post-inclusion period.

Section 9: Scenario Analysis

Scenario	Probability	Key Assumption	Implied 12-Month Price Range
Bull Case	25%	Neutron Q4 2026 success; defense backlog compounds; margins expand	$140 to $175
Base Case	45%	Neutron delayed to H1 2027; core business continues to execute; NDX inclusion supports floor	$90 to $120
Bear Case	30%	Neutron first flight fails; re-rating of growth premium; cash burn concern emerges	$45 to $65

Bull Case: 

Neutron achieves a successful first flight in Q4 2026. SpaceX's IPO drives accelerating institutional demand for the primary public-market alternative in medium-lift. Defense contract wins compound. FY2027 revenue approaches $1.5 billion. The stock re-rates toward 15 times forward revenue. KeyBanc's $135 target is the conservative end of this range.

Base Case: 

Neutron's first flight slips into H1 2027. The core business executes on Q2 and H2 2026 guidance. HASTE wins continue. Space Systems margins improve. The NDX inclusion provides a near-term support. The stock trades in a range reflecting strong current execution against uncertain Neutron timeline. Analyst consensus of approximately $107 sits in this range.

Bear Case: 

Neutron fails on first attempt. Cash burn becomes a narrative. The stock re-prices to reflect only the existing business at a more modest multiple. At $45 to $65, RKLB would trade at roughly 5 to 7 times FY2026 estimated revenue of $850 million to $900 million -- aggressive discounting for a high-growth business but not extreme in a risk-off environment.

Probability-weighted: (0.25 x $157.50) + (0.45 x $105) + (0.30 x $55) = $39.38 + $47.25 + $16.50 = $103.13

The probability-weighted outcome is approximately in line with today's price. This is not a call that the stock is cheap. It is a statement that at current prices, the market is neither dramatically overpriced nor dramatically underpriced relative to a reasonable set of assumptions.

The outcome distribution is wide. Neutron is the variable.

Section 10: Risks to the Thesis

Neutron execution risk. This is the central risk. A delayed or failed first flight reprices the stock materially. Rocket Lab's engineering track record with Electron is strong, but Neutron is a new vehicle at a new scale with new reusability requirements.

Valuation compression. At 60+ times trailing revenue, RKLB requires continued revenue acceleration. Any guidance miss or macro-driven multiple compression would be painful. High-multiple growth stocks are particularly vulnerable to rate-driven discount rate increases.

Cash burn. Rocket Lab is not yet profitable. The $2 billion liquidity position provides a runway, but it is not unlimited. If Neutron development costs exceed estimates or timelines extend, capital raising becomes a risk. Dilution is a secondary risk.

SpaceX direct competition. SpaceX with post-IPO capital can accelerate Falcon 9 production, reduce pricing, and further entrench its medium-lift dominance before Neutron is operational. The competitive window for Neutron's entry is not unlimited.

Defense budget risk. The Golden Dome program, SDA contracts, and HASTE orders all depend on sustained DoD spending. Political or budgetary changes could reduce or delay contract flow.

Customer concentration. The U.S. government represents an increasingly large share of Rocket Lab's revenue. That creates political and budget cycle risk alongside the commercial growth story.

Geopolitical manufacturing risk. Rocket Lab's New Zealand launch facility and international supply chain introduce geopolitical variables that purely domestic defense contractors do not face.

A Note on Coverage Approach

Hawkmont Research does not issue buy/sell recommendations. Our role is to provide independent, conflict-free analysis of the underlying business and let investors reach their own conclusions.

Rocket Lab is genuinely interesting. The transformation from small-launch specialist to defense prime is real and is happening in real time. The backlog growth, the HASTE franchise, the SDA contracts, and the vertical integration moat are not narrative -- they are financials. The management team has earned credibility through consistent execution against ambitious guidance.

The stock at $60 billion is a forward-looking instrument. It prices a future that includes Neutron success, continued defense contract compounding, and Space Systems margin expansion. The probability of that future is not zero. It is also not certain.

Investors who want exposure to the space economy at current prices are buying a high-quality, rapidly-growing business with a significant binary risk embedded in the form of a rocket that has not yet flown.

That is the honest summary.

---

Hawkmont Research is free. Every note, every report, no paywall. Join the desk. Join 100,000+ readers.

Subscribe

---

Disclosures and Important Notices

Hawkmont Research is an independent research firm. The authors of this report do not hold positions in any of the securities mentioned at the time of publication. This report is produced for informational and educational purposes only and does not constitute investment advice, a solicitation, or an offer to buy or sell securities.

Past performance does not guarantee future results. Investing involves risk including the potential loss of principal. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

No compensation was received from any company mentioned in this report. Hawkmont Research has no investment banking relationships with any company mentioned herein. No sell-side affiliations. No advertiser relationships.

All prices and market data as of June 18, 2026 unless otherwise noted. Financial estimates and probability assessments labeled "HMR" are Hawkmont Research estimates and should not be attributed to company guidance or sell-side consensus.

Hawkmont Research does not issue buy/sell/hold ratings on individual securities. Coverage initiation reflects our assessment that a company merits detailed independent analysis. It is not a recommendation to take any investment action.